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Abstract 
Background: Pneumonia is still one of the most frequent causes of death in the elderly. 
Complication  of  acute  lung  injury  (ALI)/acute  respiratory  distress  syndrome  (ARDS)  by 
pneumonia makes patients very ill due to severe respiratory failure. Biomarkers that can 
discriminate the presence of complicating ALI/ARDS are required for early detection. The aim 
of this research was to investigate whether soluble endothelial selectin (sES) could be a 
biomarker for ALI. 
Methods: Serum sES levels were measured in 27 pneumonia patients, who were enrolled 
between April 2006 and September 2007. Among these patients, six had ALI or a condition 
that was clinically comparable to ALI (cALI). All patients who were enrolled were successfully 
treated and survived. 
Results: Circulating sES levels were elevated in pneumonia patients with ALI/cALI, and sES 
levels decreased following treatment of their pneumonia. Univariate and multivariate logistic 
regression analyses showed that sES was the only significant factor for identifying complicating 
ALI/cALI, independently of C-reactive protein (CRP) and lactate dehydrogenase (LDH). By 
receiver operating characteristic (ROC) curve analysis, the cut-off value for sES was 40.1 
ng/mL, with a sensitivity of 0.8 and a specificity of 0.8. 
Conclusion: sES may be a useful biomarker for discriminating complicating ALI/cALI in pa-
tients with severe pneumonia. 
Key words: Pneumonia, acute lung injury, soluble endothelial selectin 
INTRODUCTION 
Pneumonia is one of the most common infectious 
diseases, and is still one of the most frequent causes of 
death in the elderly (1). In spite of advances in antibi-
otic therapy, some patients with pneumonia become 
severely  ill  due  to  delays  in  receiving  adequate 
treatment or due to comorbidities such as cancer and 
diabetes. In particular, acute lung injury (ALI)/acute 
respiratory distress syndrome (ARDS) due to severe 
pneumonia  results  in  respiratory  failure,  prolongs 
hospitalization, and sometimes causes death (2,3). The 
influx  of  neutrophils  into  lung  tissue  is  the  initial 
hallmark of ALI/ARDS (2,4). The onset and progres-Int. J. Med. Sci. 2011, 8 
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sion  of  ALI/ARDS  is  so  acute  that  it  is  sometimes 
difficult to detect the presence of ALI/ARDS, only by 
the  use  of  portable  chest  X-ray  units  in  the  early 
phase. Chest computed tomography (CT) is required 
for early diagnosis based on the ground glass shadow 
that  is  typical  of  ALI/ARDS  (5,6).  However,  per-
forming CT scans on all pneumonia patients is costly, 
and  it  is  therefore  necessary  to  develop  good  bi-
omarkers  that  can  discriminate  complicating 
ALI/ARDS, so that a quick decision can be made on 
whether a CT scan should be performed. 
Endothelial selectin (ES) is one of the cell adhe-
sion molecules expressed in the vascular endothelium 
(7). ES is induced by pro-inflammatory cytokines in 
thrombosis  (8,9),  infectious  diseases  (10),  malignant 
tumors (11) and autoimmune diseases (12), leading to 
the attachment of leukocytes to endothelial cells and 
the accumulation of leukocytes in inflamed tissues. A 
part of the extracellular portion of ES is cleaved and 
released as a soluble form (13). Circulating levels of 
soluble ES (sES) were reported to be elevated in pa-
tients  with  sepsis  and  shock  (14-16).  In  addition, 
Okajima et al. reported that hypoxia was more prev-
alent  in  patients  with  high  sES  levels  and  systemic 
inflammatory  response  syndrome  (SIRS),  compared 
to patients with normal sES levels and SIRS (17).  
Based on this background information, we hy-
pothesized that measurement of circulating sES levels 
may be useful for the discrimination of complicating 
ALI/ARDS in severe pneumonia patients. Therefore, 
we investigated sES levels in patients with commu-
nity acquired pneumonia, and assessed the associa-
tion between sES levels and complicating ALI. 
 
METHODS 
Study Subjects 
We  measured  serum  sES  levels  in  27  patients 
who were admitted to Yamagata University Hospital 
for the treatment of community acquired pneumonia 
between April 2006 and September 2007. The diagno-
sis  of  pneumonia  was  based  on  clinical  symptoms 
(cough,  sputum  production,  and  fever)  and  chest 
X-ray and chest CT findings. Patients with congestive 
heart  failure  were  excluded  from  the  analysis,  to 
avoid misdiagnosis of ALI. In addition, patients with 
malignant  tumors,  thrombotic  diseases  (deep  vein 
thrombosis  and  pulmonary  artery  thrombosis),  or 
active systemic inflammatory diseases such as colla-
gen  vascular  disease,  were  excluded,  because  sES 
levels are reported to be elevated in these disorders. 
The study protocol was approved by the institutional 
review  board  at  Yamagata  University,  and  written 
informed consent was obtained from all participating 
patients. 
Assessment of Severity of Pneumonia at Admis-
sion 
 The age, dehydration, respiratory failure, orien-
tation disturbance and low blood pressure (A-DROP) 
scoring system was used to evaluate the severity of 
pneumonia (18). This is a 6-point scale (0-5) for as-
sessing  the  clinical  severity  of  community  acquired 
pneumonia that was proposed by the Japanese Res-
piratory Society. The A-DROP scoring system assess-
es the following parameters: i) age (male ≥ 70 years, 
female ≥ 75 years); ii) dehydration [blood urea nitro-
gen (BUN) ≥ 21 mg/dL]; iii) respiratory failure [(SpO2 
≤ 90% or partial pressure of arterial oxygen (PaO2) ≤ 
60 mm Hg]; iv) orientation disturbance (confusion); 
and v) low blood pressure (systolic blood pressure ≤ 
90 mm Hg). 
Diagnosis of ALI and Clinical Status Comparable 
to ALI (cALI) 
 Generally, data on the fraction of inspired oxy-
gen (FiO2) is required to accurately diagnose whether 
or not patients have ALI (19). However, as all partic-
ipants in this study did not receive mechanical venti-
lation  or  non-invasive  positive  pressure  ventilation, 
the  accurate  FiO2  values  were  not  available  in  this 
study.  It  was  previously  reported  that  SpO2/FiO2 
(S/F)  ratios  correlate  with  PaO2/FiO2  (P/F)  ratios, 
and S/F ratios of 235 and 315 correlate with P/F ratios 
of 200 and 300, respectively, for diagnosing and fol-
lowing up patients with ALI and ARDS (20). Thus, 
hypoxic patients were defined as having “ALI/cALI” 
using  the  following  criteria:  1)  bilateral  massive 
ground glass shadow on chest X-ray and/or CT scan; 
2) no apparent findings suggesting congestive heart 
failure,  on  chest  X-ray  and  ultrasound  cardiogram; 
and  3)  requirement  of  5 L/min  or  more  of  supple-
mental oxygen therapy using a facial mask, estimated 
FiO2  ≥0.35  (21),  to  maintain  SpO2  >90%,  except  for 
patients with hypoxemia due to their primary chest 
disease. By this criterion, subjects with estimated S/F 
<257  had  a  potential  to  be  classified  as  ALI/cALI 
group. The diagnosis of ALI/cALI was made by at 
least  two  pulmonary  physicians  and  a  cardiologist, 
according  to  these  criteria.  All  pneumonia  patients 
received immediate antibiotic therapy. The etiology of 
pneumonia was aspiration (ALI/cALI group, n = 9; 
non-ALI/cALI  group,  n  =  4),  bacterial  infection 
(ALI/cALI group, n = 11; non-ALI/cALI group, n = 
1),  and  Legionella  pneumophilia  infection 
(non-ALI/cALI  group,  n  =  1).  Two  patients  in  the 
ALI/cALI group and two in the non-ALI/cALI group Int. J. Med. Sci. 2011, 8 
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received  the  neutrophil  elastase  inhibitor,  Sivelestat 
(Ono Pharmaceutical, Osaka, Japan) (22), but none of 
the patients in this study received glucocorticosteroid 
therapy. None of the patients died during the hospital 
admission, and all were successfully discharged.  
Blood Sampling and Measurement of Soluble 
Endothelial Selectin 
Repeat blood samples were obtained at intervals 
of 3 to 5 days from the time of admission until the 
patients were recovered from pneumonia, to measure 
sES  levels  and  other  biochemical  markers.  The 
time-point of blood sampling was flexibly decided by 
each doctor as needed. The median number of blood 
sampling was 2 (1 - 3) in non-ALI/cALI group, and 4 
(3.75 - 5) in ALI/cALI group [median (inter quartile 
range)].  These  samples  were  stored  frozen  at  -20°C 
until the measurements were made. sES levels were 
measured by latex photometric immunoassay (LPIA) 
(Mitsubishi Chemical Medience Corp, Tokyo, Japan) 
(17). This assay measures serum sES concentrations 
over a linear range of 5.29 to 300 ng/mL (17). It was 
reported that the normal range of the plasma sES lev-
els was 4.8 – 29.7 ng/mL (17).  
Statistical Analysis 
The  Mann-Whitney  U  test  for  non-parametric 
data  was  used  to  analyze  differences  between  two 
groups.  Multiple  comparisons  were  performed  by 
non-parametric one way analysis of variance (Krus-
kal-Wallis  test)  followed  by  the  Stu-
dent-Newman-Keuls test. Chi-square tests were used 
to evaluate differences in proportions. These compar-
isons and the logistic regression analyses were per-
formed  using  SigmaPlot  version  11  computer  soft-
ware (Systat Software, Inc., San Jose, CA, USA) and 
JMP version 8 software (SAS Institute Inc., Cary, NC, 
USA). Data in the figures are shown as mean ± SD. 
Significance was inferred for differences with P < 0.05. 
RESULTS 
The  characteristics  of  the  pneumonia  patients 
enrolled  in  this  study  are  shown  in  Table  1.  Age, 
gender,  and  the  number  of  patients  requiring  sup-
plemental oxygen did not differ significantly between 
the non-ALI/cALI and ALI/cALI groups. The length 
of  hospitalization  was  significantly  greater  in  the 
ALI/cALI group than in the non-ALI/cALI group (P 
<0.01). The A-DROP score for severity of community 
acquired pneumonia was significantly higher in the 
ALI/cALI group, compared with the non-ALI/cALI 
group (chi-square test, P <0.05). Among the labora-
tory results on arrival in hospital, only sES and lactate 
dehydrogenase (LDH) were significantly higher in the 
ALI/cALI group than in the non-ALI/cALI group (P 
<0.05). There was a trend for C-reactive protein (CRP) 
levels to be higher in the ALI/cALI group than in the 
non-ALI/cALI group, but the difference did not reach 
statistical significance (P = 0.06). Among patients with 
severe pneumonia and a A-DROP score ≥3, there was 
a trend for sES levels to be higher in the ALI/cALI 
group than in the non-ALI/cALI group, although the 
difference  was  not  statistically  significant 
(non-ALI/cALI, 39.7 ± 23.1 ng/mL; ALI/cALI, 56.0 ± 
22.2 ng/mL; P = 0.2). 
 
 
Table 1. Characteristics of the patients with pneumonia 
  non-ALI/cALI (n=21)  ALI/cALI (n=6) 
Age, years (range)  77.6 (50 - 93)  75.0 (51 - 92) 
Male gender, %  44.4  66.7 
Hospitalization, days  18.8 ± 15.1  59.3 ± 41.0** 
Use of supplemental 
oxygen, % 
66.6  100 
A-DROP score #  2 / 4 / 9 / 6 / 0 / 0  0 / 0 / 2 / 3 / 1 / 0* 
WBC, ×1000/μL #  11.50± 4.09  12.50± 5.46 
CRP, mg/dL #  11.7 ± 6.3  18.6 ± 11.0 
LDH, IU/L #  195 ± 64  274 ± 104* 
BUN, mg/dL #  18.9 ± 7.7  18.8 ± 10.0 
Na, mEq/L #  137 ± 2.6  134 ± 11.1 
Blood glucose, 
mg/dL # 
156 ± 52.9  153 ± 44.0 
Hematocrit, % #  37.0 ± 6.28  38.4 ± 5.00 
sES, ng/mL #  33.6 ± 14.8  53.0 ± 17.8* 
Data are means ± SD unless indicated otherwise. #Data obtained or 
evaluated on arrival at the hospital. 
* P < 0.05, ** P < 0.01 compared with the non-ALI/cALI group 
A-DROP score, a 6-point scale (0-5) for assessing the clinical sever-
ity of community acquired pneumonia, proposed by the Japanese 
Respiratory Society. This scoring system assesses the following 
parameters: i) age (male ≥ 70 years, female ≥ 75 years); ii) dehydra-
tion (BUN ≥ 21 mg/dL); iii) respiratory failure (SpO2 ≤ 90% or PaO2 
≤ 60 mm Hg); iv) orientation disturbance (confusion); and v) low 
blood pressure (systolic blood pressure ≤ 90 mm Hg). 
ALI, acute lung injury; BUN, blood urea nitrogen; cALI, clinical 
status comparable to ALI; CRP, C-reactive protein; LDH, lactate 
dehydrogenase; sES, soluble endothelial selectin; WBC, white blood 
cell count 
 
 
The time courses for sES, CRP and LDH accord-
ing to complicating ALI/cALI are shown in Figure 1. 
sES  levels  were  higher  in  pneumonia  patients  with Int. J. Med. Sci. 2011, 8 
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ALI/cALI than in those patients without ALI/cALI. 
sES  levels  decreased  after  commencement  of  treat-
ment in the ALI/cALI group (P = 0.017). However, in 
the  non-ALI/cALI  group  sES  levels  did  not  differ 
significantly at each time point (P = 0.075). CRP levels 
in pneumonia patients with ALI/cALI tended to be 
higher than those in patients without ALI/cALI, alt-
hough the difference was not statistically significant. 
CRP  levels  decreased  after  the  commencement  of 
treatment  in  the  non-ALI/cALI  group  (P  =  0.008). 
However, in the ALI/cALI group, the differences in 
CRP levels at each time point did not reach statistical 
significance (P = 0.07). LDH levels on day 1, days 3-4, 
and days 5-6 were higher in pneumonia patients with 
ALI/cALI than in those without ALI/cALI. However, 
the differences in LDH levels at each time point were 
not  statistically  significant  either  in  the  ALI/cALI 
group or in the non-ALI/cALI group (P = 0.444 and P 
= 0.527, respectively). 
Univariate  logistic  regression  analysis  showed 
that sES was a significant factor for identifying com-
plicating  ALI/cALI  (Table  2),  whereas  age,  gender, 
white blood cell count (WBC), CRP, LDH, BUN, Na, 
blood  glucose,  and  hematocrit  were  not  significant 
factors.  Furthermore,  multiple  logistic  regression 
analysis demonstrated that sES was an independent 
factor for identifying the presence of ALI/cALI (Table 
3). From analysis of the receiver operating character-
istic (ROC) curve, the cut-off value for sES was 40.1 
ng/mL, for discrimination of complicating ALI/cALI 
in pneumonia patients, with a sensitivity of 0.8 and a 
specificity of 0.8 (Figure 2). 
Table 2. Univariate logistic regression analysis for factors 
identifying complicating ALI/cALI in patients with pneumo-
nia 
Variable  Coefficient  SD  P value 
Age, years  0.022  0.038  0.570 
Male gender  0.144  0.489  0.769 
sES, ng/mL  -0.072  0.036  0.044 
WBC, per 1000/μL  -0.059  0.103  0.565 
CRP, mg/dL  -0.113  0.067  0.091 
LDH, IU/L  -0.012  0.007  0.073 
BUN, mg/dL  -0.044  0.049  0.368 
Na, mEq/L  0.104  0.08  0.194 
Blood glucose, mg/dL  0.0003  0.01  0.977 
Hematocrit, %  -0.035  0.078  0.658 
ALI, acute lung injury; BUN, blood urea nitrogen; cALI, clinical 
status comparable to ALI; CRP, C-reactive protein; LDH, lactate 
dehydrogenase; sES, soluble endothelial selectin; WBC, white blood 
cell count 
 
 
Figure  1.  Time  courses  of  soluble  endothelial  selectin, 
C-reactive protein and lactate dehydrogenase after com-
mencement  of  treatment  for  pneumonia,  according  to 
complicating acute lung injury.  The  time  courses  of 
soluble  endothelial  selectin  (sES,  A),  C-reactive  protein 
(CRP, B) and lactate dehydrogenase (LDH, C) are shown 
according  to  complicating  acute  lung  injury  (ALI)/clinical 
status comparable to ALI (cALI). sES levels were higher in 
pneumonia patients with ALI/cALI than in those without 
ALI/cALI.  sES  levels  decreased  after  commencement  of 
treatment in the ALI/cALI group (P = 0.017). However, sES 
levels  in  the  non-ALI/cALI  group  were  not  significantly 
different  at  each  time  point  (P  =  0.075).  CRP  levels  in Int. J. Med. Sci. 2011, 8 
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pneumonia patients with ALI/cALI tended to be higher than 
those in patients without ALI/cALI, although the difference 
was not statistically significant. CRP levels decreased after 
treatment in the non-ALI/cALI group (P = 0.008). However, 
in the ALI/cALI group, the differences in CRP levels at each 
time point did not reach statistical significance (P = 0.07). 
LDH levels on Day 1, Days 3-4, and Days 5-6 were higher in 
pneumonia patients with ALI/cALI than in those without 
ALI/cALI. However, the differences in LDH levels at each 
time point were not statistically significant either in the 
ALI/cALI group or in the non-ALI/cALI group (P = 0.444 and 
P = 0.527, respectively). * P < 0.05 compared with Day1; # P 
< 0.05 compared with the ALI/cALI group 
 
 
 
Figure 2. Determination of the soluble endothelial selectin 
(sES)  cut-off  value  for  discrimination  of  complicating 
ALI/cALI in pneumonia patients. Receiver operating char-
acteristic (ROC) curve analysis was performed to deter-
mine the sES cut-off value for discrimination of complicating 
ALI/cALI in pneumonia patients. The area under the curve 
(AUC) was 0.875, and the cut-off value was 40.1 ng/mL, 
with a sensitivity of 0.8 and a specificity of 0.8. 
 
Table 3. Multiple logistic regression analysis for factors 
identifying complicating ALI/cALI in patients with pneumo-
nia 
Variable  OR  95% CI  P value 
sES, per 1 ng/mL increase  1.099  1.012  1.260  0.021 
CRP, per 1 mg/dL increase  1.029  0.829  1.293  0.795 
LDH, per 1 IU/L increase  1.017  0.999  1.046  0.052 
ALI, acute lung injury; cALI, clinical status comparable to ALI; CI, 
confidence interval; CRP, C-reactive protein; LDH, lactate dehy-
drogenase; sES, soluble endothelial selectin; OR, odds ratio 
DISCUSSION 
This  study  demonstrated  that  circulating  sES 
levels  were  elevated  in  pneumonia  patients  with 
ALI/cALI,  and  that  sES  levels  decreased  following 
treatment for pneumonia. Although LDH levels were 
higher in pneumonia patients with ALI/cALI than in 
those without ALI/cALI, the time course of changes 
in LDH did not accord with improvement in disease 
status. Univariate and multivariate logistic regression 
analyses  revealed  that  sES  was  the  only  significant 
factor  for  identifying  complicating  ALI/cALI,  inde-
pendently  of  CRP  and  LDH.  Among  patients  with 
severe pneumonia and an A-DROP score ≥3, sES lev-
els tended to be higher in the ALI/cALI group than in 
the non-ALI/cALI group, although the difference was 
not statistically significant. Therefore, it may be pos-
sible to predict complicating ALI/cALI in pneumonia 
patients from laboratory measurements showing ele-
vated sES levels. 
Pneumonia  is  an  infectious  disease,  in  which 
pathogenic bacteria or viruses infect the lower respir-
atory tract and proliferate, leading to focal inflamma-
tion of the lungs (4). In patients with severe pneumo-
nia,  infiltrating  neutrophils  produce 
pro-inflammatory cytokines and chemokines, result-
ing in the induction of cellular adhesion molecules on 
circulating  leukocytes  and  pulmonary  endothelial 
cells (23,24). Inflamed alveolar cells, in particular al-
veolar  macrophages,  produce  chemoattractant  pro-
teins such as interleukin-8 (IL-8), which attract circu-
lating leukocytes into the lung (25). In ALI/ARDS, the 
inflamed lesion spreads over the original pneumonic 
lung segment, leading to the accumulation of leuko-
cytes in a large pulmonary area. sES is selectively ex-
pressed in vascular  endothelial cells, and  plays im-
portant roles in the accumulation of leukocytes during 
pneumonia (26). Thus, elevation of sES in pneumonia 
patients is thought to indicate the presence of major 
pulmonary  parenchymal  inflammation.  As  the  data 
from  the  present  study  demonstrates,  it  is  possible 
that sES becomes a biomarker for ALI/ARDS in pa-
tients with severe pneumonia. 
To date, WBC and CRP have been used as bi-
omarkers for the degree of inflammation, with LDH 
as a biomarker for tissue damage. We demonstrated 
that  circulating  sES  levels  were significantly  associ-
ated with complicating ALI, whereas WBC, CRP and 
LDH were not,  indicating the usefulness of sES for 
evaluating the presence of ALI in severe pneumonia. 
In  particular,  measurement  of  sES  may  be  recom-Int. J. Med. Sci. 2011, 8 
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mended  in  patients  with  severe  pneumonia  and  a 
high A-DROP score. 
The limitations of present study are: 1) since the 
study was performed at a single institute, the number 
of patients with ALI/cALI was small; 2) patients with 
very severe pneumonia, who could not provide writ-
ten informed consent due to severe respiratory failure 
comparable to a clinical status of ARDS, were not en-
rolled  in  this  study.  All  patients,  even  the  patients 
with severe pneumonia, were successfully treated and 
survived; hence, sES was not measured in very severe 
patients in the present study. Therefore, it is necessary 
to  perform  large  clinical  investigations  at  multiple 
medical institutions to confirm the usefulness of sES 
for the discrimination of complicating ALI. 
A system for rapid measurement of sES has al-
ready been established (17). In addition, the specific 
neutrophil elastase inhibitor, sivelestat, is in clinical 
use for SIRS patients (27). Neutrophil elastase induces 
IL-8 in alveolar epithelial and bronchial cells through 
activation  of  signaling  cascades  induced  by  defor-
mation of cell shape (28-30). Sivelestat has been re-
ported  to  inhibit  the  production  of  cytokines  from 
lung epithelial cells not only by inhibiting elastolytic 
activity  but  also  by  modulating  signaling  cascades 
involved  in  the  production  of  cytokines  (31).  Early 
administration  of  sivelestat  in  pneumonia  patients 
with  high  sES  levels  may  improve  the  outcome  of 
ALI/ARDS  treatment  by  attenuating  the  influx  of 
neutrophils into the lung parenchyma. 
In  conclusion,  measurement  of  sES  in  patients 
with  severe  pneumonia  may  be  useful  for  the  dis-
crimination  of  complicating  ALI/cALI.  The  clinical 
application of this potentially useful biomarker may 
improve the accuracy and rapidity of diagnosis, and 
the outcome of treatment in patients with ALI. 
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